CEPI

World-first library of vaccine-enhancing adjuvants launches | CEPI Pioneering library will serve as vaccine-adjuvant matchmaking service that creates more potent vaccines and speeds up the response to outbreaks.

📣We’re launching the world's first library of adjuvants that can be ‘taken off the shelf’ and used to develop new epidemic and pandemic vaccines.

Hosted by the UK's MHRA, the $2.5 million project will help developers select the best vaccine-adjuvant combinations: cepi.net/world-first-...

@ippsecretariat.org's 100 Days Mission Scorecard helps track progress across these countermeasures.

Worryingly it finds that of the 25 viral families likely to spawn the next pandemic, most do not have a complete set of diagnostics, therapeutics or vaccines to defend against them.

100 Days Mission: are we ready for the next pandemic? | CEPI Dr Victor Dzau reflects on the progress made towards the 100 Days Mission and the urgent need to fill gaps in our global health security.

In this new piece, Dr Victor Dzau, Co-Chair of @ippsecretariat.org, explores global progress made toward the 100 Days Mission—a goal to produce diagnostics, therapeutics, and vaccines within 100 days of identifying a viral threat with pandemic potential.
bit.ly/41jGqnL.

From coffee pods to moths – the innovation inspirations to help beat pandemics | CEPI

What do a coffee pod and a moth have to do with speeding up vaccine development and helping ensure equitable access to vaccines during a future outbreak? ☕🦋

Find out ⬇️ bit.ly/435a7ux

📣 CEPI and the Indian Council of Medical Research have signed a new MoU to strengthen collaboration on developing accessible, affordable vaccines against emerging and re-emerging infectious diseases.

New protein vaccine approach could enable faster responses to Disease X | CEPI The pioneering approach uses protein-tagging technology in nanoparticles that could also boost immune responses and allow for more targeted vaccine

Compared to traditional purification methods, POP BIO's SNAP™ nanoparticle technology could rapidly purify antigens added to protein-based infectious disease vaccines💉

CEPI is awarding up to $1.5 million to advance research into the platform:

Fighting outbreaks with FEEVA: New project could support faster approvals of vaccines | CEPI The project is led by UNSW Sydney and Monash University and supported by CEPI and Wellcome.

📣Scientists are exploring how early vaccine studies can safely support faster vaccine approvals in response to outbreaks through a new project called FEEVA.

FEEVA is funded by CEPI and @wellcometrust.bsky.social and led by @unsw.edu.au's Kirby Institute and ALEC @monashuniversity.bsky.social ⤵️

Getting ahead of pandemic threats with better, faster, AI vaccine design | CEPI

In our latest Innovation for Impact story, discover the ways in which cutting-edge #AI techniques are helping CEPI-backed scientists to reimagine how, and how quickly, the world could develop new vaccines against a potential #H5N1 pandemic threat.

bit.ly/4kU9s4x

Richard Hatchett, CEPI: “Access does not just happen.” | The CommonHealth | CSIS Podcasts Beth Cameron, Senior Advisor and Professor of the Practice at the Brown University Pandemic Center and a Senior Adviser and non-resident fellow at CSIS, hosts this inspiring conversation with Richard ...

Listen for this week's episode of A Common Health, from @csis.org, in which I had the great pleasure to host the inimitable @drrhatchett.bsky.social, CEO of @cepi.net. As always, Richard delivers not only wisdom, but also desperately needed optimism. www.csis.org/podcasts/com...

R&D experts to create playbooks that map immune markers in deadly diseases | CEPI CEPI to support PATH with US$8 million to create playbooks that map all available R&D into specific immune markers that indicate protection against

We're joining forces with @path.org to create playbooks mapping the immune markers that signal protection against Lassa fever, Mpox, Marburg and Ebola viruses.

The US$8m project will provide important insights into viral immunity, supporting vaccine development efforts cepi.net/rd-experts-c...

Nipah vaccines set to enter human trials Scientists are racing to combat one of the world’s deadliest viruses with two groundbreaking new vaccines.

Nipah virus kills up to 75% of the people it affects. And yet it has no approved vaccines to defend against it.

CEPI is a leading funder of Nipah vaccines, with two candidates on the verge of entering Phase 2 trials.

Learn more about global efforts to combat Nipah virus ⬇️ @gavi.org bit.ly/4f0xauw

We are supporting a new award launched by CIHR to support the career development of mid-career researchers in Canada.

The goal is to expand knowledge in vaccine research for infectious diseases and contribute to national and international efforts to prepare for epidemic and pandemic threats⤵️

New vaccine set for human trials in Nipah outbreak hotspot | CEPI CEPI will provide US$17.3 million to PHV to support mid-stage human trials of a Nipah vaccine candidate.

A promising vaccine candidate against the lethal #Nipah virus will soon be ready for testing in Phase 2 trials in Bangladesh, where people now die almost every year in Nipah outbreaks.

CEPI will provide $17.3 million to Public Health Vaccines to support the trial.

More info ⬇️ bit.ly/4lWdOcm

How disease survivors’ antibodies shape lifesaving vaccines Author: Selorm Avumegah, Scientist, CEPI Beyond its most obvious function of sustaining life, human blood can also reveal messages about our health, indicating whether disease might be present or whet...

Did you know that pooling antibody data from the blood of people who have recovered from a disease enables vaccinologists to understand what good protection looks like and how a vaccine might perform? 💉

Learn more ⬇️
www.linkedin.com/pulse/how-di...

What do you know about #Nipah virus, one of the world's most lethal pathogens?

Learn more in the video below or on CEPI's website: cepi.net/nipah

Learn more about this historic achievement and how its precedent could be instructive for future pandemic scenarios: bit.ly/44Ik4hT.

DYK: By the time COVAX closed in late 2023, COVAX partners—CEPI, @gavi.org, @who.int and @unicef.org —helped deliver around 2 billion COVID-19 vaccine doses to 146 countries, saving an estimated 2.7 million lives in low- and middle-income countries.

COVAX: The “world first” vaccine sharing scheme that saved millions | CEPI

Helping develop vaccines at record speed was just one half of the COVID-19 response.

Our latest article explores an equally important part of CEPI’s COVID-19 response—co-establishing COVAX, the world’s first vaccine sharing scheme 💉🌎

Read in full ⬇️ bit.ly/44Ik4hT

Building Health Resilience in West Africa: A Mobile Unit Bringing Vaccine Building Health Resilience in West Africa: A Mobile Unit Bringing Vaccine Research to Rural Communities | LSHTM

The ARC-WA project is building a mobile clinical trials unit (CTU) to bring high-quality vaccine research closer to communities. This project is led by MRCG in partnership with International Vaccine Institute (IVI) and funded by @cepi.net.

Read the full article here: tinyurl.com/yc7umyh3

Find out more about the research project, led by ‪@uantwerpen.be and University of Kinshasa: www.uantwerpen.be/en/projects/...

A CEPI-funded trial has launched in the DRC to assess an mpox vaccine in pregnant women, new mothers and infants under two💉🌍

The data could help "enable protection of these vulnerable populations" says CEPI's Mpox Disease Programme Lead, Kristine Rose: www.bavarian-nordic.com/investor/new...

"Speeding up vaccine development to 100 days could better prepare the world for the next outbreak" writes our CEO @drrhatchett.bsky.social in today’s print copy of @theguardian.com as part of the #GlobalHealthResilience campaign.

shorturl.at/pHgFD

Driving forward a new era of protection against deadly filoviruses Ebolavirus Zaire, Sudan Ebolavirus, Marburg virus—these filoviruses have been behind some of the deadliest viral outbreaks in recent memory. From the devastating 2014-16 outbreak of Ebola in West Afri...

🗞️ Our June newsletter has landed!

We spotlight a new CEPI–AdaptVac partnership to develop an all-in-one vaccine for deadly filoviruses like Marburg & Ebola, recap CEPI at the G20 Health Working Group, and share new Innovations for Impact stories on speed & access.

Read more ⬇️ bit.ly/4lptV1M

What is the future of immunisation? 💉

That’s the question I tackled this week at @gavi.org's replenishment summit, joining a powerful panel with Prof Muhammad Ali Pate, Florika Fink-Hooijer, Dr Ibrahim Sy and Derek Wallace.

📣 We are delighted to announce the appointment of Claire Hoang as CEPI's first Executive Director of People and Organisation.

cepi.net/cepi-appoint...

Pandemic speed: How rapid-response science saves lives | CEPI

At the start of the COVID-19 pandemic, CEPI sprang into action when cases of infection were in the 100s. These quick decisions established one of the largest COVID-19 vaccine portfolios and helped to save millions of lives worldwide.

➡️ Learn more cepi.net/innovations-...

Pandemic speed: How rapid-response science saves lives | CEPI

At the start of the COVID-19 pandemic, CEPI sprang into action when cases of infection were in the 100s. These quick decisions established one of the largest COVID-19 vaccine portfolios and helped to save millions of lives worldwide.

➡️ Learn more cepi.net/innovations-...

Global Summit: Health & Prosperity through Immunisation The Vaccine Alliance plans to accelerate its impact between 2026-2030, leveraging the latest innovations in vaccines and vaccine delivery to protect 500 million children and saving over 8 million live...

As Gavi's high-level pledging summit kicks off today, we call on donors worldwide to invest in Gavi and continue these life-saving efforts which make the whole world a safer place ➡️ bit.ly/4njveAX

Gavi-backed vaccines have protected an entire generation of children, saving 18 million families from the tragedy of losing a child.

Working in close partnership with countries, @gavi.org is an essential defence against the ever-increasing threat posed by infectious diseases.
#ForOurFuture

Impact of the 100 days mission for vaccines on COVID-19: a mathematical modelling study Our findings show the value of the 100 Days Mission and how these can be amplified through improvements in manufacturing and health systems equity. However, these investments must be enhanced by prior...

CEPI's #100DaysMission aims to develop new safe and effective vaccines within 100 days of a pandemic pathogen being identified.

If this were achieved for COVID-19, around 8 million lives might have been saved.

More on this in @imperialcollegeldn.bsky.social's study⬇️
bit.ly/4k4bFKe